Literature DB >> 30904173

Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.

Oliver K Jawitz1, Mohamed A Adam2, Megan C Turner3, Brian F Gilmore3, John Migaly3.   

Abstract

BACKGROUND: Despite clinical guidelines classifying T2 rectal cancer as a contraindication for transanal local excision attributable to unacceptably high rates of local recurrence, it is a practice that persists clinically. Recent clinical trials have suggested that transanal local excision in addition to neoadjuvant chemoradiation is an acceptable alternative in select patients.
METHODS: The 2004-2015 National Cancer Database was queried for patients with clinical stage T2N0M0 rectal adenocarcinoma who underwent surgical intervention. Patients were stratified by treatment with transabdominal resection or transanal local excision, both with and without neoadjuvant chemoradiation. Propensity matching was performed, and, using the Kaplan-Meier and Cox proportional hazard models, survival was compared between the groups.
RESULTS: A total of 12,021 patients met inclusion criteria, including 1,761 and 6,629 patients who underwent transabdominal resection with and without neoadjuvant chemoradiation, respectively, and 695 and 2,936 patients who underwent local transanal excision with and without neoadjuvant chemoradiation, respectively. In unadjusted analysis, patients undergoing induction therapy followed by transabdominal resection or local excision had equivalent survival. Similarly, on multivariate Cox proportional hazard regression after propensity matching, local excision was not an independent predictor of patient mortality compared with transabdominal resection (hazard ratio 0.93, 95% confidence interval 0.75-1.16).
CONCLUSION: Local transanal excision in addition to neoadjuvant chemoradiation may provide comparable survival benefit to transabdominal resection for patients with clinical stage T2N0M0 rectal cancer. Therefore, patients who refuse or are poor candidates for transabdominal resection should be considered for neoadjuvant therapy followed by transanal local excision.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30904173      PMCID: PMC6581580          DOI: 10.1016/j.surg.2019.02.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Transanal Approach to Rectal Polyps and Cancer.

Authors:  Vinay Rai; Nitin Mishra
Journal:  Clin Colon Rectal Surg       Date:  2016-03

3.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 4.  Using the National Cancer Database for Outcomes Research: A Review.

Authors:  Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

5.  Outcome of local excision of rectal carcinoma.

Authors:  D Gopaul; P Belliveau; T Vuong; J Trudel; C A Vasilevsky; R Corns; Philip H Gordon
Journal:  Dis Colon Rectum       Date:  2004-11       Impact factor: 4.585

6.  Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study.

Authors:  Krzysztof Bujko; Piotr Richter; Fraser M Smith; Wojciech Polkowski; Marek Szczepkowski; Andrzej Rutkowski; Adam Dziki; Lucyna Pietrzak; Milena Kołodziejczyk; Jerzy Kuśnierz; Tomasz Gach; Jan Kulig; Grzegorz Nawrocki; Jakub Radziszewski; Ryszard Wierzbicki; Teresa Kowalska; Wiktor Meissner; Andrzej Radkowski; Krzysztof Paprota; Marcin Polkowski; Anna Rychter
Journal:  Radiother Oncol       Date:  2013-01-17       Impact factor: 6.280

7.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

8.  Multimodality salvage of recurrent disease after local excision for rectal cancer.

Authors:  Y Nancy You; Robert E Roses; George J Chang; Miguel A Rodriguez-Bigas; Barry W Feig; Rebecca Slack; Sa Nguyen; John M Skibber
Journal:  Dis Colon Rectum       Date:  2012-12       Impact factor: 4.585

9.  Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Lindsay A Renfro; Oliver S Chow; Qian Shi; Xiomara W Carrero; Patricio B Lynn; Charles R Thomas; Emily Chan; Peter A Cataldo; Jorge E Marcet; David S Medich; Craig S Johnson; Samuel C Oommen; Bruce G Wolff; Alessio Pigazzi; Shane M McNevin; Roger K Pons; Ronald Bleday
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

10.  Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06).

Authors:  Jae Myoung Noh; Won Park; Jae-Sung Kim; Woong Sub Koom; Jin Hee Kim; Doo Ho Choi; Hee Chul Park
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

View more
  4 in total

1.  Local excision and chemoradiation for clinical node-negative anal adenocarcinoma.

Authors:  Praveen D Chatani; Dana A Dominguez; John G Aversa; Jeremy L Davis; Jonathan M Hernandez; Lily L Lai; Andrew M Blakely
Journal:  Surg Oncol       Date:  2021-03-31       Impact factor: 2.388

2.  Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk.

Authors:  I-Li Lai; Jeng-Fu You; Yih-Jong Chern; Wen-Sy Tsai; Jy-Ming Chiang; Pao-Shiu Hsieh; Hsin-Yuan Hung; Chien-Yuh Yeh; Sum-Fu Chiang; Cheng-Chou Lai; Rei-Ping Tang; Jinn-Shiun Chen; Yu-Jen Hsu
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

Review 3.  Towards personalized treatment of T2N0 rectal cancer: A systematic review of long-term oncological outcomes of neoadjuvant therapy followed by local excision.

Authors:  Roberto Peltrini; Nicola Imperatore; Maria Michela Di Nuzzo; Gianluca Pellino
Journal:  J Gastroenterol Hepatol       Date:  2022-06-03       Impact factor: 4.369

4.  Chemoradiation and Local Excision versus Total Mesorectal Excision for T2N0 Rectal Cancer: Comparison of Short- and Long-Term Outcomes from Two Prospective Studies.

Authors:  Patricio B Lynn; Maxime Van der Valk; Yvette H M Claassen; Qian Shi; Maria Widmar; Ester Bastiaannet; Cornelis Van de Velde; Julio Garcia-Aguilar
Journal:  Ann Surg       Date:  2021-07-02       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.